4.8 Article

Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 132, 期 13, 页码 -

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI151666

关键词

-

资金

  1. National Cancer Institute (NCI) Cancer Center Support Grant [NIH 5P30CA006516]
  2. NCI [1R01CA155010, U24CA224331, R01HL131768]
  3. NIH/NCI [K12CA090354, R21CA216772-01A1]
  4. Cancer Center Support Grant [5P30CA006516]
  5. Parker Institute of CancerImmunotherapy
  6. G. Harold and Leila Y. Mathers Foundation
  7. Koch Institute for Integrative Cancer Research at MIT
  8. Dana-Farber/Harvard Cancer Center
  9. Howard Hughes Medical Institute Medical Research Fellows Program
  10. US Public Health Service grants [R50CA243777, R35CA232128, R01CA173023, P01CA203655]
  11. Claudia Adams Barr Program for Innovative Cancer Research
  12. BC Children's Hospital Research Institute (BCCHRI) Investigator Grant Award Program
  13. BCCHRI Establishment Award
  14. Provincial Health Services Authority
  15. Children's & Women's Health Centre of BC
  16. BC Children's Hospital Foundation
  17. Conquer Cancer Foundation/Sontag Foundation
  18. NCI Clinical Proteomic Tumor Analysis Consortium [NIH/NCI U24CA210986, NIH/NCI U01CA214125]
  19. [NCISPORE-2P50CA101942-11A1]

向作者/读者索取更多资源

This study reveals transcriptional suppression of HLA-I antigen presentation in Merkel cell carcinoma and identifies MYCL, PRC1.1, and USP7 as regulators in this process.
Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I???low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain-and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据